Jenette Creaney

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (168)

• Hidden Targets in Cancer Immunotherapy: The Potential of “Dark Matter” Neoantigens
  Vaccines 2026 DOI: 10.3390/vaccines14010104
  +Save
• Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients
  Oxford Open Immunology 2026 DOI: 10.1093/oxfimm/iqaf008
  +Save
• Circulating stem-like exhausted CD8 T cells point to better outcomes in lung cancer
  Translational Lung Cancer Research 2025 DOI: 10.21037/tlcr-2025-509
  +Save
• Neoantigen load as a predictor of relapse in early-stage NSCLC
  Cancer immunology, immunotherapy 2025 DOI: 10.1007/s00262-025-04131-y
  +Save
• Multiple Classes of Antigen Contribute to the Antigenic Landscape of Mesothelioma
  Molecular & Cellular Proteomics 2025 DOI: 10.1016/j.mcpro.2025.100925
  +Save
• Stem-like exhausted CD8 T cells in pleural effusions predict improved survival in non-small cell lung cancer (NSCLC) and mesothelioma
  Translational Lung Cancer Research 2024 DOI: 10.21037/tlcr-24-284
  +Save
• Computational immunogenomic approaches to predict response to cancer immunotherapies
  Venkateswar Addala, Felicity Newell, John V. Pearson +4 more
  Nature Reviews Clinical Oncology 2024 DOI: 10.1038/s41571-023-00830-6
  +Save
• Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
  Current Oncology Reports 2023 DOI: 10.1007/s11912-023-01479-1
  +Save
• New Markers for Management of Mesothelioma
  Seminars in Respiratory and Critical Care Medicine 2023 DOI: 10.1055/s-0043-1769097
  +Save
• What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
  OncoImmunology 2022 DOI: 10.1080/2162402X.2022.2038403
  +Save
• Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
  Jenette Creaney, Ann‐Marie Patch, Venkateswar Addala +27 more
  Genome Medicine 2022 DOI: 10.1186/s13073-022-01060-8
  +Save
• Immune marker expression of irradiated mesothelioma cell lines
  Frontiers in Oncology 2022 DOI: 10.3389/fonc.2022.1020493
  +Save
• Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels
  Priya Ramarao-Milne, Olga Kondrashova, AM Patch +34 more
  ESMO Open 2022 DOI: 10.1016/j.esmoop.2022.100540
  +Save
• Response to “Revisiting ‘BAP1ness’ in Malignant Pleural Mesothelioma”
  Journal of Thoracic Oncology 2022 DOI: 10.1016/j.jtho.2022.05.013
  +Save
• BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma
  Journal of Thoracic Oncology 2022 DOI: 10.1016/j.jtho.2022.04.008
  +Save
• Prognostic significance of pleural effusion exhausted CD8+T cell subsets in non-small cell lung cancer and mesothelioma.
  Journal of Clinical Oncology 2022
  +Save
• Analysis of early pleural fluid samples in patients with mesothelioma
  Cancer Cytopathology 2022 DOI: 10.1002/cncy.22548
  +Save
• How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies
  Frontiers in Pharmacology 2022 DOI: 10.3389/fphar.2022.858557
  +Save
• Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology
  Cytopathology 2022 DOI: 10.1111/cyt.13015
  +Save
• Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
  Cancer Biomarkers 2022 DOI: 10.3233/CBM-210280
  +Save